Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?

Value in Health

Volumn 14, Issue 1, 2011, Pages 160-165

  Gooch, Katherine ^a   Feeny, David ^b,c   Wong, Robert L ^d   Kupper, Hartmut ^e   Pangan, Aileen L ^a   Revicki, Dennis A ^f   Van Der Heijde, Désirée ^g  

^a ABBOTT LABORATORIES   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e ABBOTT GMBH AND CO KG   (Germany)

^f UNITED BIOSOURCE CORPORATION   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis (AS); Health Utilities Index Mark 3 (HUI 3); Health related quality of life (HRQoL); Validation

Indexed keywords

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; DISCRIMINANT VALIDITY; FEMALE; HEALTH STATUS; HEALTH UTILITIES INDEX MARK 3; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; METHODOLOGY; QUESTIONNAIRE; REPRODUCIBILITY; UNITED STATES; VALIDATION STUDY;

ADULT; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SPONDYLITIS, ANKYLOSING; UNITED STATES;

EID: 79952684511     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.012     Document Type: Article

References (29)

1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4-11. (Pubitemid 44360187)
2. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31. (Pubitemid 34121668)
3. Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 2002;16:691-705.
4. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
5. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
6. van der Heijde, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
7. Davis JC Jr, Revicki D, van der Heijde D M F, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 2007;57:1050-7. (Pubitemid 47237333)
8. Revicki DA, Luo MP, Wordsworth P, et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008;35:1346-53. (Pubitemid 352000782)
9. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long term results from the ATLAS trial. Ann Rheum Dis 2009;68;922-9.
10. van der Heijde DM, Revicki DA, Gooch KL, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.
11. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
12. Reynolds S, Doward LC, Spoorenberg A, et al. The development of the ankylosing spondylitis quality of life questionnaire. Qual Life Res 1999;8:651.
13. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6. (Pubitemid 36005790)
14. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
15. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
16. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8. (Pubitemid 24285485)
17. Feeny D, Torrance GW, Furlong W. Health utilities index. In: Spilker B, ed., Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996.
18. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84. (Pubitemid 32675379)
19. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care 2002;40:113-28.
20. Harrison MJ, Davies LM, Bansback NJ, et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008;35:592-602. (Pubitemid 351500053)
21. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. (Pubitemid 32758236)
22. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Center, The Health Institute, 1993.
23. Blanchard C, Feeny D, Mahon JL, et al. Is the Health Utilities Index valid in total hip arthroplasty patients? Qual Life Res 2004;13:339-48. (Pubitemid 38392262)
24. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life in clinical trials in chronic lung disease. Thorax 1987;42:773-8. (Pubitemid 17142007)
25. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in the parents of children with asthma. Qual Life Res 1996;5:27-34. (Pubitemid 26100500)
26. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996;5:35-46. (Pubitemid 26100501)
27. Feeny D, Farris K, Côté I, et al. A cohort study found the RAND-12 and Health Utilities Mark 3 demonstrated construct validity in high-risk primary-care patients. J Clin Epidemiol 2005;58:138-41. (Pubitemid 40174921)
28. Feeny D, Huguet N, McFarland B, Kaplan MS. The construct validity of the Health Utilities Index Mark 3 in assessing mental health in population health surveys [published correction appears in Qual Life Res 2009;18:667]. Qual Life Res 2009;18:519-26.
29. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheum 1998;25:198-9.